SCHEMBL4491562

SCHEMBL4491562

CC(C)Cn1c(N(C)S(C)(=O)=O)c2c(c(O)c1=O)C(=O)N(Cc1ccc(F)c(Cl)c1)CC2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.34
PTGS2 P35354 2/20 0.34
AKR1B1 P15121 1/20 0.33
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 2/20 0.32
HTR2A P28223 2/20 0.31
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31
WDR5 P61964 1/20 0.31
MAPT P10636 1/20 0.31
EZH2 Q15910 1/20 0.30
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30
PSENEN Q9NZ42 1/20 0.30
GRM2 Q14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487189 0.91 KMT2A (0.36) PTGS1PTGS2AKR1B1ALDH1A1KMT2A
SCHEMBL4489236 0.88 ALDH1A1 (0.34) AKR1B1ALDH1A1KMT2AHTR2AWDR5
SCHEMBL4481021 0.84 AKR1B1 (0.35) PTGS1PTGS2AKR1B1ALDH1A1HTR2A
SCHEMBL4480575 0.80 POLB (0.35) PTGS1PTGS2AKR1B1ALDH1A1HTR2A
SCHEMBL4477322 0.80 AKR1B1 (0.33) AKR1B1KMT2AHTR2AWDR5EZH2
SCHEMBL4484973 0.79 P2RX7 (0.33) ALDH1A1HTR2AWDR5EZH2GRM2
SCHEMBL14441029 0.79 AKR1B1 (0.36) AKR1B1HTR2AWDR5EZH2GRM2
SCHEMBL4489034 0.77 AKR1B1 (0.38) AKR1B1HTR2AGRM2
SCHEMBL4499639 0.77 ALDH1A1 (0.35) AKR1B1ALDH1A1KMT2AMAPT
SCHEMBL4496915 0.76 AKR1B1 (0.34) AKR1B1HTR2AWDR5GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H PTGS1 3061/4885PTGS2 3965/4885AKR1B1 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.